Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio
Company will summarize topline data from the FORESEE clinical trial planned for presentation at the
SNO/ASCO Meeting in August 2024
Management call scheduled for Thursday, May 9th, 2024 at 8:30 AM ET
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets.
During the call, President and Chief Executive Officer Dr. Marc H. Hedrick will discuss the rationale for the CNSide acquisition and an overview of the assets acquired. In addition, he will also provide key updates since the September 2023 sublicense of CNSide, including topline data from the FORESEE trial, subsequent publications, interim milestones, the Company's business plan to leverage the acquired assets and planned future milestones.
Conference Call and Webcast
Thursday, May 9, 2024 @ 8:30 AM ET
Dial-in Link:
Webcast:
Participants may also pre-register any time before the call through the dial-in-link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's website under the "For Investors" section. The webcast will be available on the Company's website for 90 days following the live call.
About CNSide Test
CNSide is a laboratory developed test (LDT) based on proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets. Given the genetic changes that can occur as metastatic cancer spreads to the CNS, the evaluation of cerebrospinal fluid with CNSide provides a unique opportunity to identify biomarkers in patients with metastatic carcinoma or melanoma to help guide physicians in therapy selection. In addition, the quantitative tumor cell count assay can be used in a serial fashion to monitor the response to therapy more effectively than other current methods.
About FORESEE clinical trial
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM). Standard of Care methods to diagnose or assess the treatment response of LM (Clinical Evaluation, MRI and Cytology) have limited sensitivity and specificity. This creates challenges for physicians to manage LM or determine the best course of treatment. The goal of the FORESEE Study is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by Physicians.
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells, yet there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated.
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
公司收購了協同增效的CNSide腦脊液診斷產品組合的所有資產
公司將彙總計劃在會上發佈的FORESEE臨床試驗的頭條數據
SNO/ASCO 會議將於 2024 年 8 月舉行
管理層電話會議定於美國東部時間2024年5月9日星期四上午 8:30 舉行
得克薩斯州奧斯汀，2024年5月8日（GLOBE NEWSWIRE）——Plus Therapeutics, Inc.（納斯達克股票代碼：PSTV）（“公司”）是一家臨床階段的製藥公司，採用先進平台技術開發針對中樞神經系統（CNS）癌症的靶向放射療法，今天宣佈將於美國東部時間2024年5月9日星期四上午8點30分舉行投資者電話會議，討論對CNSide Cere的戰略收購脊液（CSF）測試資產。
在電話會議上，總裁兼首席執行官馬克·赫德里克博士將討論收購CNSide的理由以及收購資產的概述。此外，他還將提供自2023年9月CNSide分許可以來的關鍵更新，包括來自FORESEE試驗的關鍵數據、後續出版物、中期里程碑、公司利用收購資產的業務計劃和計劃中的未來里程碑。
電話會議和網絡直播
美國東部時間 2024 年 5 月 9 日星期四上午 8:30
撥入鏈接：
網絡直播：
參與者還可以在通話前隨時通過撥入鏈接進行預註冊。註冊完成後，將爲參與者提供一個帶有個性化會議代碼的撥入號碼，用於接聽電話。請在開始時間前 15 分鐘撥號。
直播結束後，將在公司網站上的 “投資者” 部分下重播。網絡直播將在現場電話會議結束後的90天內在公司網站上播出。
關於 CNSide Test
CNSide是一項實驗室開發的測試（LDT），基於專有的腫瘤細胞定量捕獲和檢測方法，並結合分析來確定可操作的分子治療靶標。鑑於轉移性癌症擴散到中樞神經系統時可能發生的基因變化，使用CNSide評估腦脊液爲識別轉移性癌或黑色素瘤患者的生物標誌物提供了難得的機會，以幫助指導醫生選擇療法。此外，定量腫瘤細胞計數測定可以連續使用，以比其他當前方法更有效地監測對治療的反應。
關於 FORESEE 臨床試驗
FORESEE研究是一項多中心的前瞻性臨床試驗，招收了可疑或確診的輕腦膜轉移（LM）的乳腺癌或非小細胞肺癌（NSCLC）患者。診斷或評估LM（臨床評估、MRI 和細胞學）治療反應的標準護理方法靈敏度和特異性有限。這給醫生管理LM或確定最佳治療方案帶來了挑戰。FORESEE研究的目標是評估CNSide在監測LM對治療的反應方面的表現，並評估CNSide對醫生做出的治療決策的影響。
關於瘦腦膜轉移瘤 (LM)
LM 是一種罕見的癌症併發症，其原發性癌症會擴散到腦脊液（CSF）以及大腦和脊髓周圍的細腦膜。所有源自實體瘤、原發性腦瘤或血液系統惡性腫瘤的惡性腫瘤都可能出現這種LM併發症，乳腺癌是與LM有關的最常見癌症，有3-5％的乳腺癌患者會出現LM。此外，肺癌、胃腸癌和黑色素瘤也可以擴散到腦脊液並導致 LM。LM 發生在大約 5% 的癌症患者中，通常爲晚期，1 年和 2 年存活率分別僅爲 7% 和 3%。LM的發病率呈上升趨勢，部分原因是癌症患者的壽命更長，部分原因是許多標準化療無法達到脊髓液中足夠的濃度來殺死腫瘤細胞，但是沒有FDA批准的專門針對LM患者的療法，如果不進行治療，他們通常會在幾周到幾個月內死於這種併發症。
關於 Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda 是一種新型的可注射放射療法，專爲以安全、有效和便捷的方式爲中樞神經系統腫瘤提供直接靶向高劑量輻射而配製，以優化患者預後。與目前批准的療法相比，Rhenium（186Re）obisbemeda有可能降低偏離靶標的風險並改善中樞神經系統癌症患者的預後，其放射劑量更具針對性和效力。Rhenium-186 是中樞神經系統治療應用的理想放射性同位素，因爲其半衰期短，β能量用於破壞癌組織，伽瑪能量用於實時成像。在Respect-GBM和Respect-LM臨床試驗中，Rhenium（186Re）obisbemeda正在評估其治療複發性膠質母細胞瘤和輕腦膜轉移的用途。Respect-GBM由美國國立衛生研究院（NIH）下屬的國家癌症研究所（NCI）的獎項支持，而Respect-LM由德克薩斯州癌症預防與研究所（CPRIT）爲期三年的1760萬美元撥款資助。
